Arbutus Biopharma Corp Annual Earnings Per Share, Basic in USD/shares from 2011 to 2023

Taxonomy & unit
us-gaap: CAD/shares and USD/shares
Description
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Summary
Arbutus Biopharma Corp quarterly/annual Earnings Per Share, Basic history and growth rate from 2011 to 2023.
  • Arbutus Biopharma Corp Earnings Per Share, Basic for the quarter ending June 30, 2024 was -0.11 USD/shares, a 10% decline year-over-year.
  • Arbutus Biopharma Corp Earnings Per Share, Basic for the twelve months ending June 30, 2024 was -0.45 USD/shares, unchanged year-over-year.
  • Arbutus Biopharma Corp annual Earnings Per Share, Basic for 2023 was -0.44 USD/shares, a 4.35% increase from 2022.
  • Arbutus Biopharma Corp annual Earnings Per Share, Basic for 2022 was -0.46 USD/shares, a 44.6% increase from 2021.
  • Arbutus Biopharma Corp annual Earnings Per Share, Basic for 2021 was -0.83 USD/shares, a 17% increase from 2020.
Earnings Per Share, Basic, Trailing 12 Months (USD/shares)
Earnings Per Share, Basic, Annual (USD/shares)
Earnings Per Share, Basic, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $0 +$0.02 +4.35% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 $0 +$0.37 +44.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$1 +$0.17 +17% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-02
2020 -$1 Jan 1, 2020 Dec 31, 2020 10-K 2022-03-03
2018 -$1 +$0.35 +22.4% Jan 1, 2018 Dec 31, 2018 10-K 2019-03-07
2017 -$2 +$5.68 +78.5% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-07
2016 -$7 -$6 -425% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-16
2015 -$1 +$0.42 +23.3% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-16
2014 -$2 -$1 -95.7% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-22
2013 -$1 -$3 -143% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-09
2012 $2.16 +$3.05 Jan 1, 2012 Dec 31, 2012 10-K 2015-03-13
2011 -$1 Jan 1, 2011 Dec 31, 2011 10-K 2014-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.